MedTrace Logo

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis

NCT02442037 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-05-15

No results posted yet for this study

Summary

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with active ulcerative colitis，randomized, single blind, controlled prospective study.

Conditions

Interventions

BIOLOGICAL

UCMSC group

Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.

OTHER

Control group(Normal saline)

Normal saline in same volume as MSCs are transplanted to patients.

Sponsors & Collaborators

  • Ivy Institute of Stem Cells Co. Ltd

    collaborator INDUSTRY

  • Affiliated Hospital to Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Bing Liu, M.D. · 307-IVY Translational Medicine Center

  • Yan Liu, M.D. · Department of gastroenterology,Affiliated Hospital to Academy of Military Medical Sciences

  • Min Min, M.D. · Department of gastroenterology,Affiliated Hospital to Academy of Military Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-05-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442037 on ClinicalTrials.gov